Jayesh Mehta MD

PubMed

• Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies.
  Eli Grunblatt, Zhiying Meng, Abigail S Baldridge, Nikita P Patel, Alexander Stanisic
  Leukemia & Lymphoma. 2025-01-07
• Recurrent Cardiac Tamponade from Multiple Myeloma While Receiving Teclistamab.
  Alexander Hurtado, Samuel T Luebbe, Emma Kilbane, Toluwalase Awoyemi, Taylor Bronson
  JACC. Case Reports. 2024-12-04
• 1 citations
  Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion.
  Kymberly D Watt, Stacey Rolak, David P Foley, Jennifer K Plichta, Sandhya Pruthi
  Transplantation. 2024-12-01

Journal Articles

• Treatment-related mortality rates on Total Therapy protocols  
  Mehta J, Blood, 9/9/2010
• Individual drug dose-intensity and outcome in myeloma  
  Mehta J, Blood, 8/31/2010
• Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib  
  Carson KR, Beckwoth LG, Mehta J, Blood, 1/1/2010
• Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic stem cell transplantation for myeloma?  
  Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J, Evens A, Frankfurt O, Altman J, Gordon L, Tallman M, Williams S, Winter J, Singhal S, Mehta J, Bone Marrow Transplant, 1/1/2009
• Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: Individual pati...  
  Kanda J, Ichinohe T, Matsuo K, Benjamin RJ, Klumpp TR, Rozman P, Blumberg N, Mehta J, Sohn SK, Uchiyama T, Transfusion, 1/1/2009
• Outpatient or inpatient stem cell transplantation: Patria est ubicunque est bene?  
  Mehta J, Dulley FL, Leuk Lymphoma, 1/1/2009
• Optimizing the CD34+ cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation  
  Mehta J, Franfurt O, Altman J, Evens A, Tallman M, Gordon L, Williams S, Winter J, Krishnamurthy J, Duffey S, Singh V, Meagher R, Grinblatt D, Kaminer L, Singhal, Leuk Lymphoma, 1/1/2009
• Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation  
  Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J, Antimicrob Agents Chemother, 1/1/2009
• Sirolimus-containing graft-versus-host disease prophylaxis in patients with lymphoma  
  Mehta J, J Clin Oncol, 1/1/2009
• Re: Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis  
  Mehta J, J Natl Cancer Inst, 1/1/2009
• High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis  
  Mehta J, Dispenzieri A, Gertz MA, Biol Blood Marrow Transplant, 1/1/2009
• The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ra...  
  Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J, Blood, 1/1/2009
• Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex  
  Craddock C, Anson J, Chu P, Dodgson A, Duncan N, Gomez C, Mehta J, Sadullah S, Subudhi C, Yin JL, Expert Opin Drug Saf, 1/1/2009
• Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: Individual pati...  
  Kanda J, Ichinohe T, Matsuo K, Benjamin RJ, Klumpp TR, Rozman P, Blumberg N, Mehta J, Sohn SK, Uchiyama T, Transfusion, 1/1/2009
• High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis  
  Mehta J, N Engl J Med, 1/1/2008
• A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma  
  Evens AM, Winter JN, Hou N, Nelson BP, Rademaker A, Patton D, Singhal S, Frankfurt O, Tallman MS, Rosen ST, Mehta J, Gordon LI, Br J Haematol, 1/1/2008
• One or two autografts for myeloma?  
  Mehta J, Blood, 1/1/2008
• Treatment for elderly patients with multiple myeloma  
  Mehta J, Lancet, 1/1/2008
• Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: what should the threshold required for apheresis be?  
  Gidron A, Singh V, Egan K, Mehta J, Bone Marrow Transplant, 1/1/2008
• The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients  
  Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan G, Singhal S, Mehta J, Bone Marrow Transplant, 1/1/2008
• Cytomegalovirus: Time for a requiem?  
  Mehta J, Blood, 1/1/2008
• Hematopoietic stem cell transplantation from unrelated donors for acute leukemia  
  Mehta J, Blood, 1/1/2008
• Current status of autologous hematopoietic stem cell transplantation in myeloma  
  Mehta J, Singhal S, Bone Marrow Transplant, 1/1/2008
• Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype  
  Sirohi B, Powles R, Singhal S, Smith K, Jones RL, Saso R, Kulkarni S, Treleaven J, Swansbury GJ, Potter M, Morgan G, Mehta J, Leuk Lymphoma, 1/1/2008
• First thalidomide clinical trial in multiple myeloma: a decade later  
  Van Rhee F, Dhodapkar M, Shaughnessy JD Jr, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B, Blood, 1/1/2008
• Join now to see all

Books/Book Chapters

• Cytokines in hematopoietic stem cell transplantation. 
  Mehta J2005
• Myeloma 
  Chapter: Solitary plasmacytoma. 
  Page 433 - 444Mehta J, Jagannath SEditors: Mehta J, Singhal S.Martin Dunitz, London2002
• Myeloma 
  Chapter: Allogeneic hematopoietic stem cell transplantation in myeloma. 
  Page 349 - 365Mehta JEditors: Mehta J, Singhal S.Martin Dunitz, London2002
• Myeloma. 
  Editors: Mehta J, Singhal S.Martin Dunitz, London2002
• Hematopoietic Stem Cell Transplantation 
  Chapter: Stem cell transplantation for myeloma - 10 years later. 
  Page 499 - 516Siegel DS, Lim SH, Tricot G, Desikan KR, Fassas A, Mehta J, Singhal S, Anaissie E, Jagannath S, Barlogie BEditors: Ho AD, Haas R, Champlin RE.Marcel Dekker, New York2000
• Allogeneic Immunotherapy for Malignant Diseases 
  Chapter: The graft-versus-myeloma effect. 
  Page 223 - 238Mehta JEditors: Barrett AJ, Jiang YZ.Marcel Dekker, New York2000
• Clinical Bone Marrow and Blood Stem Cell Transplantation, 
  Chapter: The future of bone marrow transplantation. 
  Page 1457 - 1465Mehta J, Powles REditors: Atkinson K.Cambridge University Press, CambridgeEdition 2nd,2000
• Hematology 1999. Education Book of the 41st Annual of the American Society of Hematology 
  Chapter: Sequential immunomodulation to achieve engraftment and control graft-versus-host disease across mismatched MHC barriers. 
  Page 317 - 323Henslee-Downey PJ, Godder K, Abhyankar S, Chiang KY, Lamb LS, Geier SS, Van Rhee F, Singhal S, Mehta J1999
• PPO Updates 
  Chapter: High-dose therapy and stem cell support in myeloma. 
  Page 1 - 12Mehta J, Singhal S, Desikan K, Munshi N, Badros A, Zangari M, Anaissie E, Lim S, Barlogie BEditors: De Vita VT Jr, Hellman S, Rosenberg SA.Lippincott Williams & Wilkins1999
• Current Therapy in Cancer 
  Chapter: Hematopoietic stem cell transplantation for myeloma. 
  Page 475 - 484Singhal S, Mehta J, Jagannath S, Barlogie BEditors: Foley JF, Vose JM, Armitage JO.WB Saunders, Philadelphia, PAEdition 2nd,1999
• The Clinical Practice of Stem Cell Transplantation 
  Chapter: Graft failure: diagnosis and management. 
  Page 645 - 658Mehta J, Singhal SEditors: Barrett J, Treleaven JG.Isis Medical Media, Oxford1998
• The Clinical Practice of Stem Cell Transplantation 
  Chapter: Reimmunisation after transplantation. 
  Page 745 - 756Singhal S, Mehta JEditors: Barrett J, Treleaven JG.Isis Medical Media, Oxford1998
• The Clinical Practice of Stem Cell Transplantation 
  Chapter: Pre-transplant evaluation of the patient and the donor. 
  Page 315 - 323Mehta J, Singhal SEditors: Barrett J, Treleaven JG.Isis Medical Media, Oxford1998
• Leukaemia and Associated Diseases 
  Chapter: Autologous blood and marrow transplantation. 
  Page 455 - 481Mehta J, Powles RLEditors: Whittaker JA, Holmes JA.Blackwell Science, Oxford1998
• Handbook of Adult Cancer Chemotherapy Schedules 
  Chapter: Leukaemias. 
  Page 93 - 111Mehta JEditors: Dearnaley DP, Judson I, Root T.The Medicine Group, Abingdon1995
• Leukemia & Lymphoma Reviews 4 
  Chapter: Graft-versus-leukemia reactions in clinical bone marrow transplantation. 
  Page 63 - 68Mehta JEditors: Polliack A.Harwood Academic Publishers1995
• Autologous Marrow and Blood Transplantation: Proceedings of the Seventh International Symposium, Arlington, Texas. 
  Chapter: Sequential high-dose therapy of adult acute lymphoblastic leukemia: Role of maintenance chemotherapy after peripheral blood stem cell transplantation in first remission. 
  Page 135 - 144Mehta J, Powles R, Singhal S, Horton C, Milan S, Tait D, Treleaven JEditors: Dicke KA, Keating A.The Cancer Treatment Research and Educational Institute, Arlington1995
• Medicine Update: Volume V 
  Chapter: Peripheral blood stem cell transplantation. 
  Page 285 - 292Mehta J, Singhal S, Powles REditors: Shankar PS.Association of Physicians of India, Madras1995
• A Color Atlas and Text of Bone Marrow Transplantation 
  Chapter: Primary immunodeficiency diseases. 
  Page 55 - 62Mehta JEditors: Treleaven J, Wiernik P.Mosby-Wolfe, London1995
• Oncology: A Multidisciplinary Textbook 
  Chapter: Acute leukaemias. 
  Page 261 - 273Mehta J, Powles RLEditors: Horwich A.Chapman & Hall, London1995
• Clinical Bone Marrow Transplantation: A Reference Textbook 
  Chapter: The future of bone marrow transplantation. 
  Page 736 - 740Powles RL, Mehta JEditors: Atkinson K.Cambridge University Press, Cambridge, MA1994
• API Textbook of Medicine 
  Chapter: Bone marrow transplantation. 
  Page 1036 - 1038Mehta JBEditors: Sainani GS.The Association of Physicians of India, BombayEdition 5th,1992
• Update in Internal Medicine, Volume I 
  Chapter: Myelodysplastic syndrome. 
  Page 112 - 115Mehta BC, Mehta JBEditors: Sen S.Indian College of Physicians, Calcutta1990
• API Textbook of Medicine, revised 
  Chapter: Bone marrow transplantation. 
  Page 1293 - 1295Mehta BC, Mehta JBEditors: Shah SH.The Association of Physicians of India, BombayEdition 4th,1988
• Join now to see all

Abstracts/Posters

• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Jayesh Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
  Jayesh Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Allogeneic hematopoietic stem cell transplantation for myeloma: does the melphalan dose matter? Abstract #3035
  Mehta J, Chunduri S, Dobogai L, Singhal S, Rondelli D, Blood, 1/1/2007
• Acyclovir to prevent herpes zoster in myeloma patients treated with bortezomib. Abstract #4807
  Vickrey E, Fellingham S, Mehta J, Singhal S, Blood, 1/1/2007
• Tacrolimus dosing in allogeneic hematopoietic stem cell transplant (HSCT) recipients receiving concomitant voriconazole. Abstract #4956
  Trifilio S, Pi J, Singhal S, Frankfurt O, Evens A, Gordon L, Tallman M, Winter J, Williams S, Mehta J, Blood, 1/1/2007
• Outcome of relapse after reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) - the effect of the underlying disease on survival following relap...
  Singhal S, Frankfurt O, Evens A, Gordon L, Tallman M, Williams S, Winter J, Grinblatt D, Kaminer L, Mehta J, Blood, 1/1/2007
• Maintenance chemotherapy (MC) after autotransplantation in first-remission acute lymphoblastic leukemia (ALL): single-center experience of 100 patients. Abstract #2874
  Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan G, Singhal S, Mehta J, Blood, 1/1/2007
• Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myelo...
  Richardson P, Lonial S, Jakubowiak A, Krishnan A, Wolf J, Densmore J, Singhal S, Ghobrial I, Stephenson J, Mehta J, Colson K, Francis D, Kendall T, Obadike N, Sullivan..., Blood, 1/1/2007
• Allogeneic HSCT for hematologic malignancies in 145 patients - identical biologic prognostic factors affect outcome despite different conditioning regimen intensities....
  Rondelli D, Chunduri S, Dobogai L, Mehta J, Blood, 1/1/2007
• The beneficial effects of hematopoietic cytokines on experimental stroke in rats. Proceedings of the Thirteenth Annual Conference of the American Society for Neural Th...
  Zhao LR, Singhal S, Duan WM, Mehta J, Kessler JA, Exp Neurol, 1/1/2006
• 90Y ibritumomab tiuxetan (Zevalin; 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in...
  Winter JN, Inwards S, Spies S, Wiseman G, Patton D, Erwin W, Rademaker A, Williams S, Tallman MS, Micallef I, Mehta J, Singhal S, Evens A, Zimmer M, Molina A, White C,..., Blood, 1/1/2006
• Significance of serum free light chain estimation with detectable serum monoclonal protein on immunofixation electrophoresis. Abstract #5048
  Mehta J, Stein R, Vickrey E, Resseguie W, Singhal S, Blood, 1/1/2006
• Serum free light chain measurement in myeloma patient samples with oligoclonal protein bands. Abstract #5044
  Stein R, Mehta J, Vickrey E, Resseguie W, Singhal S, Blood, 1/1/2006
• Long-acting serotonin antagonist palonosteron to prevent nausea and vomiting after high-dose melphalan and autograft in myeloma. Abstract #5239
  Trifilio S, Kaniecki K, Zook J, Pi J, Carson K, Fishman M, Masino K, Bainbridge N, Mehta J, Blood, 1/1/2006
• Correlation of serum free light chain levels with other parameters in myeloma. Abstract #5019
  Stein R, Mehta J, Vickrey E, Resseguie W, Singhal S, Blood, 1/1/2006
• Durable event-free and overall survival (EFS/OS) in mantle cell lymphoma (MCL) without rituximab: long-term follow-up of a phase II trial with intensive chemotherapy (...
  Evens AM, Winter JN, Hou N, Rademaker F, Kelemen K, Nelson B, Patton D, Frankfurt O, Williams S, Singhal S, Tallman MS, Rosen ST, Mehta J, Gordon LI, Blood, 1/1/2006
• Submyeloablative allografts for hematologic malignancies: validation of a prognostic model based on pre-transplant variables. Abstract #3036
  Mehta J, Winter J, Tallman M, Gordon L, Williams S, Frankfurt O, Evens A, Grinblatt D, Kaminer L, Meagher R, Singhal S, Blood, 1/1/2006
• Submyeloablative allogeneic HSCT for hematologic malignancies: effect of body weight. Abstract #2949
  Singhal S, Gordon L, Tallman M, Winter J, Williams S, Frankfurt O, Evens A, Meagher R, Kaminer L, Grinblatt D, Mehta J, Blood, 1/1/2006
• Voriconazole therapeutic drug monitoring: relationship between drug levels and liver function tests. Abstract #2950
  Trifilio S, Khalid MK, Pennick G, Pi J, Bainbridge N, Zook J, Mehta J, Blood, 1/1/2006
• Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Abstract #2849
  Trifilio S, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J, Blood, 1/1/2006
• Reduced-intesity allogeneic HSCT in hematologic malignancies: influence of underlying diagnosis and prior autograft on outcome. Abstract #3040
  Mehta J, Gordon L, Tallman M, Winter J, Williams S, Frankfurt O, Evens A, Grinblatt D, Kaminer L, Meagher R, Rashid K, Grabowski D, Singhal S, Blood, 1/1/2006
• Oral busulfan and cyclophosphamide or IV busulfan and fludarabine for allogeneic HSCT in hematologic malignancies? Abstract #2940
  Altman J, Venepalli N, Monreal J, Rashid K, Gordon L, Winter J, Williams S, Tallman M, Frankfurt O, Evens A, Singhal S, Mehta J, Blood, 1/1/2006
• The serum free light chain assay cannot replace 24-hour urine protein estimation in plasma cell dyscrasias. Abstract #3519
  Singhal S, Stein R, Vickrey E, Resseguie W, Mehta J, Blood, 1/1/2006
• Monitoring plasma voriconazole levels may be essential to avoid subtherapeutic levels. Abstract #594
  Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Mehta J, Blood, 1/1/2006
• Effect of impaired renal function on the outcome of submyeloablative allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Abst...
  Mehta J, Cetiner M, Gordon L, Evens A, Tallman M, Williams S, Winter J, Meagher R, Singhal S, Proc ASCO, Orlando, FL, 5/1/2005
• Join now to see all

Other

• Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders. 
  Zhao LR, Kessler J, Singhal S, Mehta J, US Patent 8,524,655
  9/3/2013
• Treatment-related mortality rates on Total Therapy protocols. 
  Mehta J, Blood e-Letter
  http://www.bloodjournal.hematologylibrary.org/cgi/eletters/115/21/4168
  9/9/2010
• Individual drug dose-intensity and outcome in myeloma. 
  Mehta J, Blood e-Letter
  http://www.bloodjournal.hematologylibrary.org/cgi/eletters/blood-2010-01-264333
  8/31/2010
• G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction. 
  Mehta J, Singhal S, Beohar N, Davidson C, Bonow R, US Patent 7,220,407
  5/22/2007
• Join now to see all